Gut microbiota, a new approach to management of polycystic ovary syndrome: a systematic review, meta-analysis and meta-evidence of 26 randomized controlled trials
Abstract
BACKGROUND: Evidence regarding the beneficial effects of biotics supplementation in polycystic ovary syndrome (PCOS) remains inconsistent. To address this discrepancy, this study aimed to investigate the impact of biotics on health outcomes in women with PCOS by conducting a systematic review and meta-analysis. METHODS: Web of Science ISI, Scopus, PubMed, Cochrane, and Embase databases were comprehensively searched up to October 2025 to identify RCTs on prebiotics, probiotics and synbiotics on health outcomes. RESULTS: Twenty-six RCTs with participants aged 25 to 29 were included in the current meta-analysis. All participants were followed up for 8 weeks to 24 weeks. Results showed that prebiotics or probiotics and synbiotics are effective in reducing weight (SMD: -0.57, 95% CI: -1.05, -0.08) and body mass index (BMI) (SMD: -0.42, 95% CI: -0.75, -0.09), waist circumference (WC) (SMD: -0.78, 95% CI: -1.28, -0.28), insulin (SMD: -0.60, 95%CI: -1.12, -0.08), HOMA-IR (SMD: -0.79, 95%CI: -1.48, -0.11), malondialdehyde (MDA) (SMD: -0.77, 95% CI: -1.17, -0.37), and triglyceride (TG) (SMD: -0.62, 95% CI: -1.08, -0.16), low-density lipoprotein-cholesterol (LDL-C) (SMD:-0.71, 95%CI: -1.21, -0.20), and total testosterone (SMD: -1.47, 95% CI: -2.32, -0.62), and led to a significant increase for total antioxidant capacity (TAC) (SMD: 0.58, 95% CI: 0.14, 1.01), and high-density lipoprotein-cholesterol (HDL-C) (SMD: 0.38, 95% CI: 0.15, 0.61). CONCLUSIONS: This meta-analysis suggests that…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.